Latest research into retatrutide peptide highlight promising potential for addressing weight and non-insulin dependent diabetes. The compound, a dual agonist of GLP-1 and GIP receptor, looks to offer enhanced weight reduction and glucose control versus existing therapies. Additional patient studies are necessary to fully determine its safety histor